Key Insights• According to the research report, "India Heparin Market Outlook, 2031," published by Actual Market Research, the India Heparin Market is expected to reach a market size of more than 1.27 Billion by 2031.• The Indian heparin market relies heavily on imported crude Active Pharmaceutical Ingredients (APIs), primarily sourced from porcine intestinal mucosa. Supply disruptions and cost shifts in upstream global supply chains have directly impacted local availability. To protect essential hospital supplies, the National Pharmaceutical Pricing Authority (NPPA) granted an unprecedented 50% increase in the price ceiling for heparin injections following a 211% surge in raw API procurement costs. This regulatory adjustment allowed formulation manufacturers to stay viable while ensuring uninterrupted access in intensive care units.• While porcine-derived heparin historically accounted for over 58% of the product distribution, disease outbreaks among swine herds and global trade friction exposed major vulnerabilities in porcine supply chains. Domestic researchers and drug manufacturers are driving breakthroughs by developing bovine-derived sources (currently the fastest-growing source segment) as well as advancing chemo-enzymatic and recombinant bio-engineered non-animal heparin pathways. These alternatives aim to mitigate religious, cultural, and animal-disease supply risks while stabilizing domestic active raw material supplies.• Prominent trade bodies supporting advocacy and quality standardisation include the Indian Pharmaceutical Association (IPA) and the Bulk Drug Manufacturers Association (BDMA), operating alongside prominent domestic and multinational market participants such as Dr.

Reddy’s Laboratories, Sanofi India, Stanex Drugs & Chemicals, Fresenius Kabi, and Burgeon Health Series.Market Outlook• Driven by national schemes promoting domestic production of key bulk drugs, Indian pharmaceutical firms are investing in local API extraction technology and backward-integrated manufacturing. Beyond fulfilling domestic emergency healthcare requirements, players are upgrading to automated pre-filled syringe (PFS) filling lines to establish India as a competitive export hub for sterile, ready-to-inject heparin formulations across Latin America, Africa, and Southeast Asia.• The forward demand for heparin in India is deeply linked to the rapid expansion of tertiary care beds and government-backed healthcare initiatives like the National Dialysis Services Programme. As the country copes with rising rates of chronic kidney disease (CKD), diabetes, and ischemic heart disease, routine outpatient dialysis sessions and invasive interventional cardiology procedures will serve as the primary volume drivers for ready-to-administer anticoagulants.Market DynamicsDriver: Rising cardiovascular disease, surgeries and critical-care demandThe Indian heparin market is being driven by the growing need for anticoagulant therapy across cardiovascular care, surgical procedures, dialysis, thrombosis management and hospital-based critical care. India’s increasing burden of cardiovascular disease, together with population ageing and improving diagnosis and treatment infrastructure, is expanding the pool of patients requiring anticoagulation. Heparin is particularly important in hospital settings because it is used to prevent and manage blood-clot formation during procedures and in conditions such as venous thromboembolism and cardiovascular disease. Challenge: Supply-chain concentration, regulatory requirements and price volatilityThe key challenge for India's heparin market is maintaining reliable and cost-effective supply of a critical anticoagulant while managing dependence on a concentrated international supply chain. Heparin is a biologically derived product, meaning its production involves specialized raw materials, stringent quality controls and complex processing.

Pharmaceutical manufacturers and hospitals therefore face risks related to raw-material availability, API quality, regulatory compliance, supplier qualification, import logistics and price fluctuations. Trend: Increasing adoption of LMWH and evolution toward higher-value heparin productsA major trend in India is the increasing importance of low-molecular-weight heparin (LMWH) alongside conventional unfractionated heparin. LMWH products are increasingly used for thromboprophylaxis and venous thromboembolism prevention and are relevant across surgical, cardiovascular and other hospital applications. This reflects a broader shift in anticoagulation toward products that can offer more predictable anticoagulant effects and convenient subcutaneous administration in appropriate clinical settings.Procurement and Industry Impact • Heparin is a critical hospital product, so buyers are likely to place greater weight on qualified suppliers, API source diversification, GMP/CoA/DMF documentation and continuity of supply. PharmaCompass recorded multiple Indian API sourcing requirements, including a 25 kg USP-grade heparin sodium commercial requirement in March 2025 and a 40 kg commercial requirement in November 2025.• India's heparin-sodium import market reportedly grew at a 17.31% CAGR from 2020-2024, with imports increasing 10.68% from 2023 to 2024. At the same time, the high concentration of supplying countries means procurement teams have an incentive to qualify multiple sources and develop longer-term contracts.• Indian manufacturers are active across heparin sodium and enoxaparin API/FDF production; for example, industry listings identify Indian suppliers producing bovine and porcine heparin sodium as well as enoxaparin sodium. Greater domestic capability can reduce dependence on imported inputs, shorten lead times and increase competition among suppliers, potentially benefiting hospital and pharmaceutical procurement.Segment AnalysisIndia Heparin Market By Product Type• LMWH is the most clinically prominent modern heparin format in India, particularly for thromboprophylaxis and treatment of venous thromboembolism.

Indian critical-care guidance recommends LMWH for DVT prevention and specifically prefers LMWH over DOACs for prophylaxis in acutely critically ill patients. A key feature of the Indian market is the growing preference for convenient subcutaneous LMWH therapy in hospital settings. Enoxaparin is particularly important because it can provide predictable anticoagulation without the continuous infusion and intensive laboratory adjustment generally associated with UFH.• UFH retains an important position in India because of its rapid onset, short duration and controllability. It is particularly useful when clinicians need to change the intensity of anticoagulation quickly or anticipate an invasive procedure. The product has a strong role in intensive care, cardiovascular interventions and patients with significant renal impairment. Indian PE treatment guidance, for example, specifically identifies UFH as preferred for hemodynamically unstable patients requiring thrombolysis, patients requiring multiple procedures and patients with renal failure.• ULMWH is a specialized rather than mainstream segment of the Indian heparin market.

Its commercial opportunity is linked to pharmaceutical innovation aimed at achieving more controlled anticoagulant characteristics through further molecular-weight reduction. Unlike conventional UFH and established LMWH products, ULMWH competes more on pharmacological differentiation and product innovation than on sheer hospital volume.India Heparin Market By Application• Coronary artery disease is an important heparin application because anticoagulation is required in several acute coronary and interventional settings. UFH remains particularly valuable where clinicians need rapid intravenous anticoagulation and immediate dose adjustment. LMWH, particularly enoxaparin, provides an alternative for selected acute coronary and thrombotic situations. The coexistence of UFH and LMWH creates a procedure-versus-predictability dynamic within India's cardiovascular market.• DVT represents one of the strongest applications for LMWH in India. Indian critical-care recommendations explicitly support either UFH or LMWH for DVT prophylaxis, while LMWH is preferred over DOACs for prophylaxis in acutely critically ill patients.

The Indian market is particularly influenced by hospital protocols covering postoperative patients, immobilized patients and critically ill patients. This makes DVT demand closely connected to hospital admission volumes and thromboprophylaxis practices, rather than only diagnosed DVT cases.• Pulmonary Embolism is an important acute-care application in India because treatment guidelines support prompt anticoagulation when clinical suspicion is high and there is no contraindication. India's Ministry of Health treatment guidance identifies subcutaneous LMWH and intravenous UFH as initial anticoagulation options for patients with high clinical probability of PE. LMWH and fondaparinux are generally preferred over UFH, while UFH has specific advantages in unstable patients, those requiring procedures and those with renal failure.• Kidney dialysis is a distinctive application because heparin is used to prevent clotting in the extracorporeal circuit during hemodialysis. UFH has traditionally been important because its pharmacological profile allows anticoagulation to be controlled during a dialysis session. LMWH can also be incorporated into dialysis protocols, creating competition based on dosing convenience, institutional practice and patient characteristics.• The others category includes surgical prophylaxis, intensive-care anticoagulation, catheter-related applications, extracorporeal procedures and other hospital uses.

India's critical-care guidance recommends pharmacological thromboprophylaxis for appropriate critically ill patients and recognizes both UFH and LMWH as options. It also specifically recommends UFH or selected LMWH products when severe renal dysfunction affects anticoagulant selection.India Heparin Market By Source• Porcine-derived heparin is the leading source segment in India. India is an important pharmaceutical manufacturing and export base, but it also relies on international supply channels for pharmaceutical-grade heparin and related materials. UN Comtrade data show that in 2024 India exported US$61.1 million of the relevant HS 3001 category covering heparin and its salts and imported US$55.4 million. The importance of porcine material reflects the established global heparin supply chain, in which porcine intestinal mucosa is a major source of pharmaceutical heparin.• Bovine-derived heparin is a strategically interesting alternative source in India because it can reduce dependence on the porcine supply chain and broaden the potential raw-material base. Its importance is increasing from a source-diversification perspective, even though porcine heparin remains the larger segment.

Bovine sourcing can also be commercially relevant for manufacturers serving markets where animal-origin preferences, religious considerations or customer specifications influence the choice of anticoagulant source.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Heparin Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Low Molecular Weight Heparin (LMWH)• Unfractionated Heparin (UFH)• Ultra-Low Molecular Weight Heparin (ULMWH)By Application• Coronary Artery Disease• Deep Vein Thrombosis• Pulmonary Embolism• Kidney Dialysis• OthersBy Source• Porcine-derived• Bovine-derived.